Trial · NCT04533737
Results by group176
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 176
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Having Psoriasis Area and Severity Index (PASI) 100 Response at Week 16 | Arm 1 (Brodalumab + Dummy 1) | 53.4 | 95% Confidence Interval 40.0 to 66.8 | percentage of subjects | |
| Having Psoriasis Area and Severity Index (PASI) 100 Response at Week 16 | Arm 2 (Guselkumab + Dummy 2) | 35.9 | 95% Confidence Interval 23.0 to 48.7 | percentage of subjects | |
| Time to PASI 100 Response (Summarized as the Cumulative Incidence for Achieving PASI 100 at Each Timepoint, Stratified by Weight) | Arm 1 (Brodalumab + Dummy 1) | <=100 kg Week 1 | 0 | 95% Confidence Interval 0 to 0 | percentage of subjects |
| Time to PASI 100 Response (Summarized as the Cumulative Incidence for Achieving PASI 100 at Each Timepoint, Stratified by Weight) | Arm 2 (Guselkumab + Dummy 2) | <=100 kg Week 1 | 0 | 95% Confidence Interval 0 to 0 | percentage of subjects |
| Time to PASI 100 Response (Summarized as the Cumulative Incidence for Achieving PASI 100 at Each Timepoint, Stratified by Weight) | Arm 1 (Brodalumab + Dummy 1) | <=100 kg Week 2 | 4.5 | 95% Confidence Interval 0.8 to 13.7 | percentage of subjects |
| Time to PASI 100 Response (Summarized as the Cumulative Incidence for Achieving PASI 100 at Each Timepoint, Stratified by Weight) | Arm 2 (Guselkumab + Dummy 2) | <=100 kg Week 2 | 0 | 95% Confidence Interval 0 to 0 | percentage of subjects |
| Time to PASI 100 Response (Summarized as the Cumulative Incidence for Achieving PASI 100 at Each Timepoint, Stratified by Weight) | Arm 1 (Brodalumab + Dummy 1) | <=100 kg Week 4 | 22.7 | 95% Confidence Interval 11.7 to 36.0 | percentage of subjects |
| Time to PASI 100 Response (Summarized as the Cumulative Incidence for Achieving PASI 100 at Each Timepoint, Stratified by Weight) | Arm 2 (Guselkumab + Dummy 2) | <=100 kg Week 4 | 2.3 | 95% Confidence Interval 0.2 to 10.7 | percentage of subjects |
| Time to PASI 100 Response (Summarized as the Cumulative Incidence for Achieving PASI 100 at Each Timepoint, Stratified by Weight) | Arm 1 (Brodalumab + Dummy 1) | <=100 kg Week 6 | 34.1 | 95% Confidence Interval 20.5 to 48.1 | percentage of subjects |
| Time to PASI 100 Response (Summarized as the Cumulative Incidence for Achieving PASI 100 at Each Timepoint, Stratified by Weight) | Arm 2 (Guselkumab + Dummy 2) | <=100 kg Week 6 | 14.0 | 95% Confidence Interval 5.6 to 26.1 | percentage of subjects |
| Time to PASI 100 Response (Summarized as the Cumulative Incidence for Achieving PASI 100 at Each Timepoint, Stratified by Weight) | Arm 1 (Brodalumab + Dummy 1) | <=100 kg Week 8 | 40.9 | 95% Confidence Interval 26.3 to 55.0 | percentage of subjects |
| Time to PASI 100 Response (Summarized as the Cumulative Incidence for Achieving PASI 100 at Each Timepoint, Stratified by Weight) | Arm 2 (Guselkumab + Dummy 2) | <=100 kg Week 8 | 23.3 | 95% Confidence Interval 11.9 to 36.8 | percentage of subjects |
| Time to PASI 100 Response (Summarized as the Cumulative Incidence for Achieving PASI 100 at Each Timepoint, Stratified by Weight) | Arm 1 (Brodalumab + Dummy 1) | <=100 kg Week 10 | 45.5 | 95% Confidence Interval 30.2 to 59.5 | percentage of subjects |
| Time to PASI 100 Response (Summarized as the Cumulative Incidence for Achieving PASI 100 at Each Timepoint, Stratified by Weight) | Arm 2 (Guselkumab + Dummy 2) | <=100 kg Week 10 | 27.9 | 95% Confidence Interval 15.4 to 41.8 | percentage of subjects |
| Time to PASI 100 Response (Summarized as the Cumulative Incidence for Achieving PASI 100 at Each Timepoint, Stratified by Weight) | Arm 1 (Brodalumab + Dummy 1) | <=100 kg Week 12 | 61.4 | 95% Confidence Interval 45.1 to 74.1 | percentage of subjects |
| Time to PASI 100 Response (Summarized as the Cumulative Incidence for Achieving PASI 100 at Each Timepoint, Stratified by Weight) | Arm 2 (Guselkumab + Dummy 2) | <=100 kg Week 12 | 27.9 | 95% Confidence Interval 15.4 to 41.8 | percentage of subjects |
| Time to PASI 100 Response (Summarized as the Cumulative Incidence for Achieving PASI 100 at Each Timepoint, Stratified by Weight) | Arm 1 (Brodalumab + Dummy 1) | <=100 kg Week 14 | 61.4 | 95% Confidence Interval 45.1 to 74.1 | percentage of subjects |
| Time to PASI 100 Response (Summarized as the Cumulative Incidence for Achieving PASI 100 at Each Timepoint, Stratified by Weight) | Arm 2 (Guselkumab + Dummy 2) | <=100 kg Week 14 | 30.2 | 95% Confidence Interval 17.2 to 44.3 | percentage of subjects |
| Time to PASI 100 Response (Summarized as the Cumulative Incidence for Achieving PASI 100 at Each Timepoint, Stratified by Weight) | Arm 1 (Brodalumab + Dummy 1) | <=100 kg Week 16 | 63.6 | 95% Confidence Interval 47.4 to 76.1 | percentage of subjects |
| Time to PASI 100 Response (Summarized as the Cumulative Incidence for Achieving PASI 100 at Each Timepoint, Stratified by Weight) | Arm 2 (Guselkumab + Dummy 2) | <=100 kg Week 16 | 39.5 | 95% Confidence Interval 24.9 to 53.8 | percentage of subjects |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04533737/results